Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03960268 · ClinicalTrials.gov registry record · Early Phase 1
Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab
A Early Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03960268 is a Early Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 10 participants.
The verdict
NCT03960268, a Early Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Phase 0 Study of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.
Interventions
- DRUG Brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-05-28 |
| Est. Completion | 2020-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03960268
The ClinicalTrials.gov registry entry for NCT03960268 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brodalumab is the first listed.
NCT03960268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03960268 about?
NCT03960268 is a clinical study titled "Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab". Phase 0 Study of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.
What is the current status of trial NCT03960268?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-05-28. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03960268?
The interventions under investigation include: Brodalumab (DRUG).
Who is sponsoring clinical trial NCT03960268?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.